CA2690746C - Phenothizine compounds for treating mild cognitive impairment - Google Patents

Phenothizine compounds for treating mild cognitive impairment Download PDF

Info

Publication number
CA2690746C
CA2690746C CA2690746A CA2690746A CA2690746C CA 2690746 C CA2690746 C CA 2690746C CA 2690746 A CA2690746 A CA 2690746A CA 2690746 A CA2690746 A CA 2690746A CA 2690746 C CA2690746 C CA 2690746C
Authority
CA
Canada
Prior art keywords
use according
diaminophenothiazine compound
mtc
treatment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2690746A
Other languages
English (en)
French (fr)
Other versions
CA2690746A1 (en
Inventor
Claude Michel Wischik
Dominic Venay Harbaran
Gernot Riedel
Serena Deiana
Elizabeth Anne Goatman
Damon Jude Wischik
Alison Dorothy Murray
Roger Todd Staff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CA2690746A1 publication Critical patent/CA2690746A1/en
Application granted granted Critical
Publication of CA2690746C publication Critical patent/CA2690746C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2690746A 2007-06-19 2008-06-17 Phenothizine compounds for treating mild cognitive impairment Active CA2690746C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
US60/945,006 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (2)

Publication Number Publication Date
CA2690746A1 CA2690746A1 (en) 2008-12-24
CA2690746C true CA2690746C (en) 2018-01-02

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690746A Active CA2690746C (en) 2007-06-19 2008-06-17 Phenothizine compounds for treating mild cognitive impairment

Country Status (16)

Country Link
US (1) US9211294B2 (https=)
EP (1) EP2167095B1 (https=)
JP (1) JP5725605B2 (https=)
CN (1) CN101820884B (https=)
AU (1) AU2008265045B2 (https=)
BR (1) BRPI0813670A2 (https=)
CA (1) CA2690746C (https=)
DK (1) DK2167095T3 (https=)
ES (1) ES2739546T3 (https=)
HR (1) HRP20191513T1 (https=)
HU (1) HUE045460T2 (https=)
MY (1) MY177001A (https=)
PL (1) PL2167095T3 (https=)
PT (1) PT2167095T (https=)
SI (1) SI2167095T1 (https=)
WO (1) WO2008155533A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
CA3027974C (en) * 2007-10-03 2022-03-15 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
CN102958525B (zh) 2010-04-30 2017-05-24 普罗瑟塔抗病毒股份有限公司 抗病毒化合物
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
EP2951149B1 (en) * 2013-01-30 2018-10-10 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
WO2016133995A1 (en) * 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
KR102592614B1 (ko) * 2016-07-25 2023-10-24 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
DK3826639T3 (da) 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
AU2024231880A1 (en) 2023-03-03 2025-09-11 Taurx Therapeutics Management Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
AU2005286235C1 (en) 2004-09-23 2013-08-22 TauRx Therapeutics Management Ltd Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC)
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
MY162640A (en) * 2006-03-29 2017-06-30 Wista Lab Ltd Thioninium compounds and their use
PL2004155T3 (pl) 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
DK3121169T3 (da) * 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser

Also Published As

Publication number Publication date
US9211294B2 (en) 2015-12-15
BRPI0813670A2 (pt) 2014-12-30
ES2739546T3 (es) 2020-01-31
JP2010530403A (ja) 2010-09-09
EP2167095B1 (en) 2019-05-29
PT2167095T (pt) 2019-08-06
HRP20191513T1 (hr) 2019-11-29
PL2167095T3 (pl) 2019-11-29
US20100184752A1 (en) 2010-07-22
JP5725605B2 (ja) 2015-05-27
WO2008155533A3 (en) 2009-02-19
CA2690746A1 (en) 2008-12-24
AU2008265045B2 (en) 2014-02-27
DK2167095T3 (da) 2019-07-29
EP2167095A2 (en) 2010-03-31
CN101820884A (zh) 2010-09-01
CN101820884B (zh) 2013-08-28
AU2008265045A1 (en) 2008-12-24
MY177001A (en) 2020-09-01
WO2008155533A2 (en) 2008-12-24
SI2167095T1 (sl) 2019-09-30
HUE045460T2 (hu) 2019-12-30

Similar Documents

Publication Publication Date Title
CA2690746C (en) Phenothizine compounds for treating mild cognitive impairment
Berk et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial
KR102654569B1 (ko) 외상 후 스트레스 장애의 치료를 위한 제제
CN107810002B (zh) 左乙拉西坦的延时释放药物组合物
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
EA037187B1 (ru) Способ и композиция для лечения когнитивного расстройства
US20190231768A1 (en) Pridopidine for treating drug induced dyskinesias
US20250302773A1 (en) Compositions comprising meai and n-acylethanolamines and uses thereof
US20110217387A1 (en) Pharmaceutical composition for treatment of fibromyalgia
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
CN114072154B (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
RU2824584C2 (ru) Метилтиониний в качестве усилителя когнитивной функции
WO2023243659A1 (ja) 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
HK40052880A (en) Extended release pharmaceutical compositions of levetiracetam
HK1252154B (zh) 左乙拉西坦的延时释放药物组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130524

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250528

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250528